Related Experiment Videos

Evaluation of the ILAR criteria for juvenile idiopathic arthritis

M Krumrey-Langkammerer1, R Häfner

  • 1Pediatric Rheumatology Hospital Garmisch-Partenkirchen, Germany.

The Journal of Rheumatology
|November 16, 2001
PubMed

Insights

New criteria for juvenile idiopathic arthritis (JIA) need refinement. Minor classification changes could improve JIA categorization, particularly for "other arthritis" cases, enhancing diagnostic homogeneity.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Classification

Background:

  • The International League of Associations for Rheumatology (ILAR) proposed new classification criteria for chronic childhood arthritis, using the term juvenile idiopathic arthritis (JIA) and subdividing it into seven categories.
  • Evaluation of these proposed criteria is ongoing within the pediatric rheumatology community.

Purpose of the Study:

  • To evaluate the applicability of the proposed ILAR classification criteria for juvenile idiopathic arthritis (JIA).
  • To identify limitations in the current JIA classification and suggest modifications for improved diagnostic accuracy and homogeneity.

Main Methods:

  • Analysis of data from 200 consecutive pediatric patients diagnosed with rheumatic diseases.
  • Assessment of patient data against the proposed ILAR JIA classification criteria.

Main Results:

  • 172 out of 200 patients met the criteria for JIA.
  • A significant proportion (15.7%, 27 patients) were classified as "other arthritis": 16 met criteria for multiple categories, and 11 fit none.
  • Specific subgroups within "other arthritis" showed characteristics suggesting potential for new categories, such as "extended oligoarthritis at onset".

Conclusions:

  • Minor adjustments to the JIA classification criteria are proposed to reclassify 24 of the 27 "other arthritis" patients into specific categories.
  • The introduction of an "extended oligoarthritis at onset" category is recommended to better accommodate patients with specific joint involvement patterns, rheumatoid factor negative polyarthritis, positive antinuclear antibodies, or chronic uveitis.
  • These suggested changes aim to enhance the homogeneity and clinical utility of JIA patient groups.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...